ZyVersa amends pro forma to reflect reverse merger; adds ~$105M IPR&D asset

ZyVersa Therapeutics, Inc.

Pro forma updated to forward merger (ZyVersa as VIE); ~$105M IPR&D/goodwill recorded on balance sheet.
Combined pro forma net loss: $20.96M for 9mo Sep 2022, $8.91M for FY2021.
Actual redemptions of 7.67M shares for $78.0M; 6.72M shares issued to ZyVersa equity holders.
Transaction costs $5.2M settled via $1.7M Series B preferred and $3.5M cash; deferred underwriting $3.4M settled in Series B.
Pro forma total assets $113.4M as of Sep 30, 2022, primarily from IPR&D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.